coursework-banner

Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients

Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients

Walden University Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients-Step-By-Step Guide

 

This guide will demonstrate how to complete the Walden University  Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients assignment based on general principles of academic writing. Here, we will show you the A, B, Cs of completing an academic paper, irrespective of the instructions. After guiding you through what to do, the guide will leave one or two sample essays at the end to highlight the various sections discussed below.

 

How to Research and Prepare for Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients                   

 

Whether one passes or fails an academic assignment such as the Walden University Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients   depends on the preparation done beforehand. The first thing to do once you receive an assignment is to quickly skim through the requirements. Once that is done, start going through the instructions one by one to clearly understand what the instructor wants. The most important thing here is to understand the required format—whether it is APA, MLA, Chicago, etc.

 

After understanding the requirements of the paper, the next phase is to gather relevant materials. The first place to start the research process is the weekly resources. Go through the resources provided in the instructions to determine which ones fit the assignment. After reviewing the provided resources, use the university library to search for additional resources. After gathering sufficient and necessary resources, you are now ready to start drafting your paper.

 

How to Write the Introduction for Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients                   

The introduction for the Walden University Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients  is where you tell the instructor what your paper will encompass. In three to four statements, highlight the important points that will form the basis of your paper. Here, you can include statistics to show the importance of the topic you will be discussing. At the end of the introduction, write a clear purpose statement outlining what exactly will be contained in the paper. This statement will start with “The purpose of this paper…” and then proceed to outline the various sections of the instructions.

 

How to Write the Body for Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients                   

 

After the introduction, move into the main part of the Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients   assignment, which is the body. Given that the paper you will be writing is not experimental, the way you organize the headings and subheadings of your paper is critically important. In some cases, you might have to use more subheadings to properly organize the assignment. The organization will depend on the rubric provided. Carefully examine the rubric, as it will contain all the detailed requirements of the assignment. Sometimes, the rubric will have information that the normal instructions lack.

 

Another important factor to consider at this point is how to do citations. In-text citations are fundamental as they support the arguments and points you make in the paper. At this point, the resources gathered at the beginning will come in handy. Integrating the ideas of the authors with your own will ensure that you produce a comprehensive paper. Also, follow the given citation format. In most cases, APA 7 is the preferred format for nursing assignments.

 

How to Write the Conclusion for Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients                   

 

After completing the main sections, write the conclusion of your paper. The conclusion is a summary of the main points you made in your paper. However, you need to rewrite the points and not simply copy and paste them. By restating the points from each subheading, you will provide a nuanced overview of the assignment to the reader.

 

How to Format the References List for Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients                   

 

The very last part of your paper involves listing the sources used in your paper. These sources should be listed in alphabetical order and double-spaced. Additionally, use a hanging indent for each source that appears in this list. Lastly, only the sources cited within the body of the paper should appear here.

Stuck? Let Us Help You

 

Completing assignments can sometimes be overwhelming, especially with the multitude of academic and personal responsibilities you may have. If you find yourself stuck or unsure at any point in the process, don’t hesitate to reach out for professional assistance. Our assignment writing services are designed to help you achieve your academic goals with ease. 

 

Our team of experienced writers is well-versed in academic writing and familiar with the specific requirements of the Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients assignment. We can provide you with personalized support, ensuring your assignment is well-researched, properly formatted, and thoroughly edited. Get a feel of the quality we guarantee – ORDER NOW. 

 

Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients

When pediatric clients present with mood disorders, the
process of assessing, diagnosing, and treating them can be quite complex.
Children not only present with different signs and symptoms than adult clients
with the same disorders, but they also metabolize medications much differently.
As a result, psychiatric mental health nurse practitioners must exercise
caution when prescribing psychotropic medications to these clients. For this
Assignment, as you examine the client case study in this week’s Learning
Resources, consider how you might assess and treat pediatric clients presenting
with mood disorders.

Note: This Assignment is the first of 10 assignments that
are based on interactive client case studies. For these assignments, you will
be required to make decisions about how to assess and treat clients. Each of
your decisions will have a consequence. Some consequences will be
insignificant, and others may be life altering. You are not expected to make
the “right” decision every time; in fact, some scenarios may not have a “right”
decision. You are, however, expected to learn from each decision you make and
demonstrate the ability to weigh risks versus benefits to prescribe appropriate
treatments for clients.

Learning Objectives

Students will: Assess client factors and history to develop personalized
plans of antidepressant therapy for pediatric clients

Analyze factors that influence pharmacokinetic and
pharmacodynamic processes in pediatric clients requiring antidepressant therapy

Evaluate efficacy of treatment plans

Analyze ethical and legal implications related to
prescribing antidepressant therapy to pediatric clients

Learning Resources

Note: To access this week’s required library resources,
please click on the link to the Course Readings List, found in the Course
Materials section of your Syllabus.

Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS :Factors that Influence Pharmacokinetic and Pharmacodynamic Processes in Pediatric Clients

Required Readings

Note: All Stahl resources can be accessed through the Walden
Library using this link. This link will take you to a log-in page for the
Walden Library. Once you log into the library, the Stahl website will appear.

Stahl, S. M. (2013).
Stahl’s essential psychopharmacology: Neuroscientific basis and practical
applications (4th ed.). New York, NY: Cambridge University Press.

Note: To access the following chapters, click on the Essential
Psychopharmacology, 4th ed tab on the Stahl Online website and select the
appropriate chapter. Be sure to read all sections on the left navigation bar
for each chapter.

Chapter 6, “Mood Disorders”

Chapter 7, “Antidepressants”

Stahl, S. M. (2014b). The prescriber’s guide (5th ed.). New
York, NY: Cambridge University Press.

Note: To access the following medications, click on the The
Prescriber’s Guide, 5th ed tab on the Stahl Online website and select the
appropriate chapter. Be sure to read all sections on the left navigation bar
for each chapter.

Review the following medications:

amitriptyline

bupropion

citalopram

clomipramine

desipramine

desvenlafaxine

doxepin

duloxetine

escitalopram

fluoxetine

fluvoxamine

imipramine

ketamine

mirtazapine

nortriptyline

paroxetine

selegiline

sertraline

trazodone

venlafaxine

vilazodone

vortioxetine

Magellan Health, Inc. (2013). Appropriate use of
psychotropic drugs in children and adolescents: A clinical monograph. Retrieved
from http://www.magellanhealth.com/media/445492/magellan-psychotropicdrugs-0203141.pdf

Rao, U. (2013).
Biomarkers in pediatric depression. Depression & Anxiety, 30(9), 787–791.
doi:10.1002/da.22171

Note: Retrieved from Walden Library databases.

Vitiello, B. (2012). Principles in using psychotropic medication
in children and adolescents. In J. M. Rey (Ed.), IACAPAP e-Textbook of Child
and Adolescent Mental Health. Geneva: International Association for Child and
Adolescent Psychiatry and Allied Professions. Retrieved from
http://iacapap.org/wp-content/uploads/A.7-PSYCHOPHARMACOLOGY-072012.pdf

Poznanski, E., &
Mokros, H. (1996). Child Depression Rating Scale–Revised. Los Angeles, CA:
Western Psychological Services.

Note: Retrieved from Walden Library databases.

Required Media

Laureate Education (2016e). Case study: An African American
child suffering from depression [Interactive media file]. Baltimore, MD:
Author.

Note: This case study will serve as the foundation for this
week’s Assignment.

Optional Resources

El Marroun, H., White, T., Verhulst, F., & Tiemeier, H.
(2014). Maternal use of antidepressant or anxiolytic medication during
pregnancy and childhood neurodevelopmental outcomes: A systematic review.
European Child & Adolescent Psychiatry, 23(10), 973–992.
doi:10.1007/s00787-014-0558-3

Gordon, M. S., & Melvin, G. A. (2014). Do
antidepressants make children and adolescents suicidal? Journal of Pediatrics
and Child Health, 50(11), 847–854. doi:10.1111/jpc.12655

Seedat, S. (2014). Controversies in the use of
antidepressants in children and adolescents: A decade since the storm and where
do we stand now? Journal of Child & Adolescent Mental Health, 26(2), iii–v.
doi:10.2989/17280583.2014.938497

To prepare for this Assignment:

Review this week’s Learning Resources. Consider how to
assess and treat pediatric clients requiring antidepressant therapy.

The Assignment

Examine Case Study: An African American Child Suffering From
Depression. You will be asked to make three decisions concerning the medication
to prescribe to this client. Be sure to consider factors that might impact the
client’s pharmacokinetic and pharmacodynamic processes.

At each decision point stop to complete the following:

Decision #1

Which decision did you select?

Why did you select this decision? Support your response with
evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision?
Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve
with Decision #1 and the results of the decision. Why were they different?

Decision #2

Why did you select this decision? Support your response with
evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision?
Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve
with Decision #2 and the results of the decision. Why were they different?

Decision #3

Why did you select this decision? Support your response with
evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision?
Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve
with Decision #3 and the results of the decision. Why were they different?

Also include how ethical considerations might impact your
treatment plan and communication with clients.

Topic 1 DQ 1

Oct 3-5, 2022

What would spirituality be according to your own worldview? How do you believe that your conception of spirituality would influence the way in which you care for patients?

According to Hart (1994, p. 23), spirituality is the way a person lives out their beliefs in daily life and the way they “respond to the end conditions of individual existence” (Bożek, Nowak, , & Blukacz, 2020).A sense of peace and well-being are generated by spirituality, which is defined by faith, a search for life’s meaning and purpose and a feeling of belonging with one another. Through spiritual connection life satisfaction may increase or make it easier to accommodate illness or disability. Although, the idea of spirituality encompasses a huge range of personal experiences and convictions. Every individual has a unique perspective on spirituality. We may develop more comprehensive and compassionate healthcare systems by addressing the spiritual needs of our patients.

Nurses are being required more and more to recognize and respond to spiritual issues because of the emphasis on holistic care and meeting the requirements of each individual patient. Physical healing, pain relief, and personal development might result from attending to the patient’s spiritual needs. The nurse must attend to the patient’s emotional as well as physical demands in order to meet their total needs.The way in which we provide patient care would be influenced by our personal understanding of spirituality. For example, my spiritual beliefs consist of treating everyone with respect, compassion, care and equality regardless of their health status, race, spiritual view, gender, etc. I can take that into consideration into my practice by providing culturally competent, holistic care so I can better understand what I can do to assist the patient’s physical, spiritual, and mental wellbeing. Further, hospitals are held liable by The Joint Commission (TJC) for upholding patient rights, which includes making accommodations for cultural, religious, and spiritual values. The bodies, minds, and spirits of patients must all be taken into consideration by healthcare practitioners and systems (Swihart, Yarrarapu, & Martin, 2021).

Bożek, A., Nowak, P. F., & Blukacz, M. (2020). The Relationship Between Spirituality, Health-Related Behavior, and Psychological Well-Being. Frontiers in Psychology11https://doi.org/10.3389/fpsyg.2020.01997

Swihart, D.L., Yarrarapu ,S.N.S & Martin R.L. (2021). Cultural Religious Competence In Clinical Practice. StatPearls Publishing https://www.ncbi.nlm.nih.gov/books/NBK493216/

 

The patient in the case study is Katie, an 8-year-old Caucasian female who visits the clinic with her parents. Her PCP referred her for psychiatric assessment after Katie’s teacher mentioned that she could have ADHD. The teacher completed the “Conner’s Teacher Rating Scale-Revised” tool, which shows that Katie has poor concentration levels, easy distractibility, poor memory, and spelling, reading, and calculation difficulties. Her attention span is limited, and she only pays attention to things she is interested in. Furthermore, Katie shows minimal interest in school work, rarely completes her tasks and homework, and barely follows instructions. She is diagnosed with ADHD (inattentive presentation). The patient factors that will impact prescribing include age, ADHD presentation, medication adverse effects, potential drug interactions, and treatment preferences (Nazarova et al., 2022).

Decision #1

Ritalin (methylphenidate) chewable tablets 10 mg orally in the Morning.

Why Did You Select This Decision?

Ritalin was selected because it is the first medication choice for the short-term management of ADHD in children and adolescents (Nazarova et al., 2022). Drechsler et al. (2020) explain that the psychostimulants Ritalin and amphetamine are the most effective agents in treating primary ADHD symptoms, and they have a good efficacy and adverse event profile.

Why Did You Not Select The Other Two Options Provided In The Exercise?

Wellbutrin has a slow onset of action than stimulants like Ritalin. Thus Ritalin was preferred over it due to its fast onset of action and better efficacy in treating ADHD symptoms (Coghill et al., 2021). Intuniv XR was not selected because the drug’s full effects on alleviating ADHD symptoms are usually seen after some weeks of administration Drechsler et al. (2020). Thus, it was not selected as the initial drug since the options included Ritalin, which has immediate symptom reduction.

What I Was Hoping To Achieve By Making This Decision

I anticipated that Ritalin would significantly lower Katie’s ADHD symptoms of inattention and distractibility immediately (Drechsler et al., 2020). I also hoped these would help improve her academic performance by increasing her concentration and attention.

Ethical Considerations Impact on Treatment Plan and Communication

The practitioner has a moral duty to promote the best outcomes for the patient without compromising her safety. This impacted the treatment since the practitioner had to select Ritalin since its efficacy is established and it has a good adverse event profile.

Decision #2

Change to Ritalin LA 20 mg orally daily in the MORNING.

Why Did You Select This Decision?

Ritalin was changed to long-acting (LA) to ensure the drug’s effects would be sustained the entire school day. The average duration of the clinical effect of the Ritalin immediate-release formulation is 3-4 hours (Steingard et al., 2019). Thus it could not sustain the effects, unlike the LA formulation, whose duration of clinical effect is up to 14 hours, making it a better option for this patient (Patrick et al., 2019).

Why Did You Not Select The Other Two Options Provided In The Exercise?

Continuing the initial Ritalin dose was not ideal because of its duration of clinical effect of 3-4 hours (Steingard et al., 2019). This would not be sustainable in maintaining the drug’s positive effect in promoting the patient’s attention and concentration the entire day. Besides, the patient was not switched to Adderall because Ritalin positively alleviated ADHD symptoms. Treatment guidelines recommend switching a drug if there is no improvement or when adverse effects are reported (Coghill et al., 2021).

What I Was Hoping To Achieve By Making This Decision

I hoped that changing Ritalin from Immediate release to long-acting formulation would help to maintain Katie’s concentration in class the whole day (Patrick et al., 2019). I also hoped that the teacher would report improvement in Katie’s attention in class and academic improvement.

Ethical Considerations Impact on Treatment Plan and Communication

            The PMHNP had an ethical duty to uphold beneficence by selecting the treatment to improve patient outcomes. This impacted the treatment plan since the PMHNP had to change Ritalin to a LA formulation with more sustained outcomes than the immediate release.

Decision #3

Maintain current Ritalin LA dose and reevaluate in 4 weeks.

Reason for this Decision

Ritalin LA effectively sustained the patient’s attention span, leading to improved academic performance. Thus, maintaining the dose was the ideal option. Steingard et al. (2019) explain that the LA formulations have become the core of ADHD treatment.

Why Did You Not Select The Other Two Options Provided In The Exercise?

Ritalin LA was not increased to 30 mg since the initial dose effectively alleviated symptoms. Increasing the dose increases the risk of side effects Patrick et al., 2019. The patient had an HR of 92 and had no palpitations; thus, an EKG was unnecessary.

What I Was Hoping To Achieve By Making This Decision

I hoped Ritalin LA would continuously improve Katie’s attention span without compromising her safety (Drechsler et al., 2020).

Ethical Considerations Impact on Treatment Plan and Communication

The practitioner had to select the intervention that would promote the patient’s safety, which upholds nonmaleficence.

Conclusion

Katie presented with ADHD symptoms like inattention, poor concentration, and distractibility. Medication decisions may be influenced by the patient’s age, ADHD presentation, adverse drug effects, potential drug interactions, and treatment preferences (Nazarova et al., 2022). She was started on Ritalin IR, which effectively improved her ADHD symptoms. However, the drug’s effects were not sustained the whole day due to its short duration of clinical effect of 3-4 hours (Steingard et al., 2019). Consequently, the PMHNP switched Ritalin to LA since it has a longer duration of clinical effect of up to 14 hours. This would help sustain Katie’s concentration the whole day (Patrick et al., 2019). Wellbutrin and Intuniv were not prescribed since they take longer than Ritalin to demonstrate a positive effect in reducing ADHD symptoms.

 

 

References

Coghill, D., Banaschewski, T., Cortese, S., Asherson, P., Brandeis, D., Buitelaar, J., … & Simonoff, E. (2021). The management of ADHD in children and adolescents: bringing evidence to the clinic: a perspective from the European ADHD Guidelines Group (EAGG). European Child & Adolescent Psychiatry, 1-25. doi: 10.1007/s00787-021-01871-x

Drechsler, R., Brem, S., Brandeis, D., Grünblatt, E., Berger, G., & Walitza, S. (2020). ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics51(5), 315–335. https://doi.org/10.1055/s-0040-1701658

Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022). Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers in pharmacology13, 1066988. https://doi.org/10.3389/fphar.2022.1066988

Patrick, K. S., Radke, J. L., Raymond, J. R., Koller, L., Nguyen, L. V., Rodriguez, W., & Straughn, A. B. (2019). Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy39(6), 677–688. https://doi.org/10.1002/phar.2190

Steingard, R., Taskiran, S., Connor, D. F., Markowitz, J. S., & Stein, M. A. (2019). New Formulations of Stimulants: An Update for Clinicians. Journal of Child and adolescent psychopharmacology29(5), 324–339. https://doi.org/10.1089/cap.2019.0043